BillionToOne is a leading molecular diagnostics company dedicated to advancing disease detection at the molecular level. Their proprietary technology, known as Quantitative Counting Templates (QCTs™), empowers the detection and measurement of tiny DNA fragments at a single base-pair resolution. This technology is a breakthrough in prenatal screening and oncology, enabling accurate risk assessment for fetal genetic conditions and monitoring cancer therapy effectiveness. BillionToOne’s UNITY Screen™ assesses fetal risks using maternal blood samples, making prenatal testing more efficient. The company is committed to enhancing healthcare by making molecular testing more accurate and accessible, evidenced by its recognition as the Diagnostics Company of the Year and significant funding achievements.